
Tenaya Therapeutic (TNYA) Stock Forecast & Price Target
Tenaya Therapeutic (TNYA) Analyst Ratings
Bulls say
Tenaya Therapeutics is a promising clinical-stage biotechnology company that is focused on developing therapies for heart diseases through three interrelated platforms: Gene Therapy, Cellular Regeneration, and Precision Medicine. The recent FDA clearance for the clinical hold on TN-201, and the encouraging clinical results for TN-401, demonstrate the company's strong scientific capabilities and potential for success. The company has a diverse pipeline and a strong team of experienced scientists and medical professionals, which positions it well for future growth and success.
Bears say
Tenaya Therapeutics is a clinical-stage company focused on gene therapy and precision medicine for heart disease, but their early-stage programs and lack of human proof-of-concept data present significant risks and potential delays to bringing their products to market. Additionally, there is competition in the rare genetic disorders space and an uncertain market potential for their potential one-time gene therapy treatments. With a need for continued fundraising and a lack of a clear pathway to profitability, there are significant financial risks associated with investing in Tenaya Therapeutics.
This aggregate rating is based on analysts' research of Tenaya Therapeutic and is not a guaranteed prediction by Public.com or investment advice.
Tenaya Therapeutic (TNYA) Analyst Forecast & Price Prediction
Start investing in Tenaya Therapeutic (TNYA)
Order type
Buy in
Order amount
Est. shares
0 shares